According to Luoxin Pharmaceutical's announcement, from January 1 to June 30, 2026, net profit attributable to shareholders of listed companies is expected to be 4,900-51 million yuan, an increase of 176.91% to 188.22% year on year; net profit after deducting non-recurring profit and loss is 3,000-32 million yuan, an increase of 1203.97%-1290.90% year on year. The increase in performance was mainly due to the year-on-year increase in sales revenue of the core innovative drug tigoracin tablets, the completion of the 20% equity disposal of Luoxin Anjoravita Pharmaceutical to confirm investment income, and the completion of 100% equity disposal of Shandong Lecang Pharmaceutical at the end of 2025. Related losses will no longer affect the 2026 results.

According to Luoxin Pharmaceutical's announcement, from January 1 to June 30, 2026, net profit attributable to shareholders of listed companies is expected to be 4,900-51 million yuan, an increase of 176.91% to 188.22% year on year; net profit after deducting non-recurring profit and loss is 3,000-32 million yuan, an increase of 1203.97%-1290.90% year on year. The increase in performance was mainly due to the year-on-year increase in sales revenue of the core innovative drug tigoracin tablets, the completion of the 20% equity disposal of Luoxin Anjoravita Pharmaceutical to confirm investment income, and the completion of 100% equity disposal of Shandong Lecang Pharmaceutical at the end of 2025. Related losses will no longer affect the 2026 results.